Literature DB >> 21848814

The WxxxE effector EspT triggers expression of immune mediators in an Erk/JNK and NF-κB-dependent manner.

Benoit Raymond1, Valerie F Crepin, James W Collins, Gad Frankel.   

Abstract

Enteropathogenic Escherichia coli (EPEC), enterohaemorrhagic E. coli (EHEC) and Citrobacter rodentium colonize their respective hosts while forming attaching and effacing lesions. Their infection strategy relies on translocation of a battery of type III secretion system effectors, including Map, EspM and EspT, which belong to the WxxxE/SopE family of guanine nucleotide exchange factors. Using the C. rodentium mouse model we found that EspT triggers expression of KC and TNFα in vivo. Indeed, a growing body of evidence suggests that, in addition to subversion of actin dynamics, the SopE and the WxxxE effectors activate signalling pathways involved in immune responses. In this study we found that EspT induces expression of the pro-inflammatory mediators cyclooxygenase-2 (COX-2) an enzyme involved in production of prostaglandin E(2) (PGE2), interleukin (Il)-8 and Il-1β in U937 human macrophages by activating the nuclear factor kappa-B (NF-κB), the extracellular signal-regulated kinases 1 and 2 (Erk1/2) and c-Jun N-terminal kinase (JNK) pathways. Since EspT modulates the activation of Cdc42 and Rac1, which mediates bacterial invasion into epithelial cells, we investigated the involvement of these Rho GTPases and bacterial invasion on pro-inflammatory responses and found that (i) Rac1, but not Cdc42, is involved in EspT-induced Il-8 and Il-1β secretion and (ii) cytochalasin D inhibits EspT-induced EPEC invasion into U937 but not Il-8 or Il-1β secretion. These results suggest that while EPEC translocates a number of effectors (i.e. NleC, NleD, NleE, NleH) that inhibit inflammation, a subset of strains, which encode EspT, employ an infection strategy that also involves upregulation of immune mediators.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21848814      PMCID: PMC4977063          DOI: 10.1111/j.1462-5822.2011.01666.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  50 in total

1.  Activation of NF-kappaB and IL-8 by Yersinia enterocolitica invasin protein is conferred by engagement of Rac1 and MAP kinase cascades.

Authors:  Guntram A Grassl; Michael Kracht; Agnès Wiedemann; Elke Hoffmann; Martin Aepfelbacher; Christoph von Eichel-Streiber; Erwin Bohn; Ingo B Autenrieth
Journal:  Cell Microbiol       Date:  2003-12       Impact factor: 3.715

Review 2.  Animal models of inflammatory bowel disease: lessons from enteric infections.

Authors:  Lars Eckmann
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

3.  The enteropathogenic Escherichia coli type III secretion system effector Map binds EBP50/NHERF1: implication for cell signalling and diarrhoea.

Authors:  Nandi Simpson; Rob Shaw; Valerie F Crepin; Rosanna Mundy; Anthony J FitzGerald; Nicola Cummings; Ania Straatman-Iwanowska; Ian Connerton; Stuart Knutton; Gad Frankel
Journal:  Mol Microbiol       Date:  2006-04       Impact factor: 3.501

4.  Characterization of Escherichia coli DNA lesions generated within J774 macrophages.

Authors:  E Schlosser-Silverman; M Elgrably-Weiss; I Rosenshine; R Kohen; S Altuvia
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

5.  Salmonella secreted factor L deubiquitinase of Salmonella typhimurium inhibits NF-kappaB, suppresses IkappaBalpha ubiquitination and modulates innate immune responses.

Authors:  Gaëlle Le Negrate; Benjamin Faustin; Kate Welsh; Markus Loeffler; Maryla Krajewska; Patty Hasegawa; Sohini Mukherjee; Kim Orth; Stan Krajewski; Adam Godzik; Donald G Guiney; John C Reed
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

6.  The S. Typhimurium effector SopE induces caspase-1 activation in stromal cells to initiate gut inflammation.

Authors:  Andreas J Müller; Claudia Hoffmann; Marlies Galle; Aeke Van Den Broeke; Mathias Heikenwalder; Laura Falter; Benjamin Misselwitz; Marcus Kremer; Rudi Beyaert; Wolf-Dietrich Hardt
Journal:  Cell Host Microbe       Date:  2009-08-20       Impact factor: 21.023

7.  A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-κB for degradation.

Authors:  Jaclyn S Pearson; Patrice Riedmaier; Olivier Marchès; Gad Frankel; Elizabeth L Hartland
Journal:  Mol Microbiol       Date:  2011-02-22       Impact factor: 3.501

8.  The T3SS effector EspT defines a new category of invasive enteropathogenic E. coli (EPEC) which form intracellular actin pedestals.

Authors:  Richard Bulgin; Ana Arbeloa; David Goulding; Gordon Dougan; Valerie F Crepin; Benoit Raymond; Gad Frankel
Journal:  PLoS Pathog       Date:  2009-12-11       Impact factor: 6.823

9.  Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota.

Authors:  Bärbel Stecher; Riccardo Robbiani; Alan W Walker; Astrid M Westendorf; Manja Barthel; Marcus Kremer; Samuel Chaffron; Andrew J Macpherson; Jan Buer; Julian Parkhill; Gordon Dougan; Christian von Mering; Wolf-Dietrich Hardt
Journal:  PLoS Biol       Date:  2007-10       Impact factor: 8.029

10.  EspT triggers formation of lamellipodia and membrane ruffles through activation of Rac-1 and Cdc42.

Authors:  Richard R Bulgin; Ana Arbeloa; Jade C S Chung; Gad Frankel
Journal:  Cell Microbiol       Date:  2008-10-30       Impact factor: 3.715

View more
  19 in total

1.  Influence of NleH effector expression, host genetics, and inflammation on Citrobacter rodentium colonization of mice.

Authors:  Leigh Ann Feuerbacher; Philip R Hardwidge
Journal:  Microbes Infect       Date:  2014-03-05       Impact factor: 2.700

2.  The Complete Genome of the Atypical Enteropathogenic Escherichia coli Archetype Isolate E110019 Highlights a Role for Plasmids in Dissemination of the Type III Secreted Effector EspT.

Authors:  Tracy H Hazen; David A Rasko
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

Review 3.  Infection strategies of enteric pathogenic Escherichia coli.

Authors:  Abigail Clements; Joanna C Young; Nicholas Constantinou; Gad Frankel
Journal:  Gut Microbes       Date:  2012-03-01

4.  Association of Atypical Enteropathogenic Escherichia coli with Diarrhea and Related Mortality in Kittens.

Authors:  Victoria E Watson; Megan E Jacob; James R Flowers; Sandra J Strong; Chitrita DebRoy; Jody L Gookin
Journal:  J Clin Microbiol       Date:  2017-06-28       Impact factor: 5.948

Review 5.  In vitro and in vivo model systems for studying enteropathogenic Escherichia coli infections.

Authors:  Robyn J Law; Lihi Gur-Arie; Ilan Rosenshine; B Brett Finlay
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

Review 6.  Detection of enteric pathogens by the nodosome.

Authors:  A Marijke Keestra; Andreas J Bäumler
Journal:  Trends Immunol       Date:  2013-11-22       Impact factor: 16.687

7.  Tir Triggers Expression of CXCL1 in Enterocytes and Neutrophil Recruitment during Citrobacter rodentium Infection.

Authors:  Valerie F Crepin; Maryam Habibzay; Izabela Glegola-Madejska; Marianne Guenot; James W Collins; Gad Frankel
Journal:  Infect Immun       Date:  2015-06-15       Impact factor: 3.441

8.  Roles of Eicosanoids in Regulating Inflammation and Neutrophil Migration as an Innate Host Response to Bacterial Infections.

Authors:  Austin E F Sheppe; Mariola J Edelmann
Journal:  Infect Immun       Date:  2021-07-15       Impact factor: 3.441

9.  The type III secretion effector NleF of enteropathogenic Escherichia coli activates NF-κB early during infection.

Authors:  Mitchell A Pallett; Cedric N Berger; Jaclyn S Pearson; Elizabeth L Hartland; Gad Frankel
Journal:  Infect Immun       Date:  2014-09-02       Impact factor: 3.441

10.  The interplay between the Escherichia coli Rho guanine nucleotide exchange factor effectors and the mammalian RhoGEF inhibitor EspH.

Authors:  Alexander R C Wong; Abigail Clements; Benoit Raymond; Valerie F Crepin; Gad Frankel
Journal:  mBio       Date:  2012-01-17       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.